NOVUS THERAPEUTICS INC's ticker is NVUS and the CUSIP is 67011N105. A total of 20 filers reported holding NOVUS THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $54,435,000 | +3631.0% | 3,183,314 | 0.0% | 0.68% | +3157.1% |
| Q2 2020 | $1,459,000 | +17.6% | 3,183,314 | 0.0% | 0.02% | 0.0% |
| Q1 2020 | $1,241,000 | -32.8% | 3,183,314 | 0.0% | 0.02% | -19.2% |
| Q4 2019 | $1,846,000 | -6.5% | 3,183,314 | 0.0% | 0.03% | -29.7% |
| Q3 2019 | $1,974,000 | -38.6% | 3,183,314 | 0.0% | 0.04% | -26.0% |
| Q2 2019 | $3,215,000 | -68.5% | 3,183,314 | +25.5% | 0.05% | -68.4% |
| Q1 2019 | $10,199,000 | +151.3% | 2,537,110 | 0.0% | 0.16% | +110.7% |
| Q4 2018 | $4,059,000 | -65.7% | 2,537,110 | 0.0% | 0.08% | -47.6% |
| Q3 2018 | $11,848,000 | -33.3% | 2,537,110 | 0.0% | 0.14% | -32.5% |
| Q2 2018 | $17,760,000 | +38.9% | 2,537,110 | 0.0% | 0.21% | +33.3% |
| Q1 2018 | $12,787,000 | +24.1% | 2,537,110 | 0.0% | 0.16% | +22.3% |
| Q4 2017 | $10,301,000 | -22.1% | 2,537,110 | 0.0% | 0.13% | +3.2% |
| Q3 2017 | $13,218,000 | -10.9% | 2,537,110 | 0.0% | 0.13% | -19.2% |
| Q2 2017 | $14,842,000 | – | 2,537,110 | – | 0.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 2,537,110 | $4,059,000 | 0.08% |
| Boxer Capital, LLC | 324,383 | $519,000 | 0.06% |
| B. Riley Wealth Advisors, Inc. | 120,219 | $193,000 | 0.03% |
| CARY STREET PARTNERS INVESTMENT ADVISORY LLC | 10,600 | $22,000 | 0.02% |
| Sequoia Financial Advisors, LLC | 22,500 | $36,000 | 0.00% |
| VANGUARD GROUP INC | 42,403 | $68,000 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 10,944 | $18,000 | 0.00% |
| UBS Group AG | 1,061 | $2,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 23,424 | $36,000 | 0.00% |